Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aethlon Medical ( (AEMD) ) has provided an update.
On November 12, 2025, Aethlon Medical announced its financial results for the fiscal second quarter ending September 30, 2025, reporting a significant reduction in operating expenses by 48% compared to the previous year. The company highlighted its ongoing clinical progress, including recruitment for the second cohort of its Australian oncology trial and collaboration with UCSF on Long COVID research. Aethlon’s Nasdaq compliance issues have been resolved, maintaining its listing, and the company continues to advance its Hemopurifier technology with new evaluations for simplified blood treatment systems.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The company is engaged in clinical trials and research collaborations to advance its Hemopurifier technology, which is designed to remove viruses and tumor-derived extracellular vesicles from circulation.
Average Trading Volume: 314,034
Technical Sentiment Signal: Sell
Current Market Cap: $3.31M
Learn more about AEMD stock on TipRanks’ Stock Analysis page.